Page 44 - Hal Barron News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FTSE 100 pharma giant must persuade investors its pipeline has promising drugs as it prepares to spin off its consumer health division

News Category Global Banking & Finance Reviews Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 – Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19 – SAN FRANCISCO and LONDON, Dec. 17, 2020 — Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today an...

Senior Editor The Food and Drug Administration has given the green light to GlaxoSmithKline for Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Lupus nephritis is a serious inflammation of the kidneys caused by systemic lupus erythematosus, or SLE, the most common form of lupus, which can lead to end-stage kidney disease, requiring dialysis or a kidney transplant. The approval extends the current indication in the United States to include both SLE and LN for both the intravenous and subcutaneous formulations...

-3.32% gained 1.3% in premarket trading on Friday, the day after the biotech and GlaxoSmithKline GSK, +0.36% said they started dosing patients in a late-stage clinical trial for an experimental antibody-based COVID-19 treatment. The Phase 3 study is part of the National Institutes of Health's Accelerating COVID-19 Therapeutic Interventions and Vaccines Program. The companies are testing VIR-7831 in patients who have been hospitalized due to COVID-19 infections. The investigational treatment "has the potential to neutralize the virus and kill infected cells, [which] coul...

GlaxoSmithKline And Vir Biotechnology Kick Off ACTIV-3 Covid Trial Thu, 17th Dec 2020 21:45 (Alliance News) - GlaxoSmithKline PLC and Vir Biotechnology Inc said Thursday they have started the US National Institutes of Health sponsored ACTIV-3 trial for evaluating VIR-7831 in hospitalised adults with Covid-19. The pair said that the first patient has been dosed in a new sub-trial of the NIH's Accelerating Covid-19 Therapeutic Interventions & Vaccines Program Phase 3 clinical trial. This trial is designed to evaluate the safety and efficacy of VIR-7831 for the treatment of hospitalised adults w...